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Purpose: To investigate the protective effect of clusterin on oxidative stress-induced cell death of human corneal
endothelial cells.
Methods: Human corneal endothelial cells (HCECs) were cultured according to previously published methods. With
treatment of various concentrations (0-50 mM) of tert-butyl hydroperoxide (tBHP) or clusterin, reactive oxygen species
(ROS) producrion was measured using an oxidationsensitive fluorescent probe and 2′7′-dichlorofluorescin diacetate
(DCFH-DA). Cell viability was assayed with a Cell Counting Kit-8.
Results: In HCECs, DCF-DA staining revealed that cells treated with a higher concentration of tBHP had higher
fluorescent intensity than cells treated with clusterin, compared to control cells. Clusterin significantly inhibited tBHP-
induced ROS production. Cell viability decreased with higher tBHP concentration. Cells treated with clusterin had higher
viability than control cells at 5 mM tBHP. Clusterin effectively protected HCECs from ROS-induced cell death.
Conclusions: Our data suggest that clusterin may protect HCECs from oxidative injury-mediated cell death via inhibition
of ROS production.
Oxidative stress has been implicated in a wide spectrum
of patho-physiological events, including Fuchs’ endothelial
dystrophy [1], bullous keratopathy [1,2], and senescence [1].
Although bullous keraopathy patients and Fuchs dystrophy
patients  often  have  similar  clinical  symptoms,  their
pathophysiologic  pathways  are  not  different.  The
peroxynitrite pathway is induced by oxidative stress in Fuchs’
dystrophy and, on the other side, malonidialdehyde is present
as a toxic byproduct of lipid peroxidation induced by reactive
oxygen species (ROS) in bullous keratopathy [1]. Tert-butyl
hydroperoxide (tBHP) is a ROS generation agent that causes
lipid  peroxidation  [3].  tBHP  has  been  known  to  decrease
cellular proliferative life span and increase the proportion of
cells’ positive senescence-associated enzyme activity. Thus,
tBHP  has  been  used  for  the  induction  of  stress-induced
premature senescence [3].
Clusterin, a heterodimeric glycoprotein, was first isolated
from ram rete testis fluid [4]. Clusterin has been described to
attribute to many cellular physiologic functions, including
cell–cell  interactions  [4,5],  complement  inhibition,  lipid
transportation, cell survival, and apoptosis [6]. Clusterin, also
called apoprotein J, is induced under cytotoxic conditions to
protect  cells  from  cytotoxic  stress  [3,7-12].  it  has  been
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reported that clusterin is associated with many degenerative
diseases,  such  as  Alzheimer’s  disease  [13-15]  and
Huntington's  disease  [16].  Clusterin  has  been  reported  to
express in normal corneal endothelilum [17], to increase in
corneal endothelium with Fuchs’ endothelial dystrophy [18,
19],  and  to  decrease  in  corneas  with  bullous  keratopthay
[18]. It has been predicted that clusterin may play a role in the
pathophysiology  of  these  diseased  corneas.  However,  the
function of clusterin in human corneal endothelial cells under
oxidative stress is not clearly understood.
In the present study, we investigated the protective effect
of  clusterin  on  the  oxidative  stress-induced  cell  death  of
human corneal endothelial cells..
METHODS
Culture of human corneal endothelial cells: Human corneal
endothelial  cells  were  cultured  according  to  previously
published methods [20,21]. Corneal endothelial cells from the
remnant  donor  tissue  after  corneal  transplantation  were
harvested attached to Descemet’s membrane on or before the
7th day after death. The ages of the donor tissues were 40 years
old (donor A) and 33 years old (donor B). The endothelial cells
and Descemet’s membrane complex were incubated for 1 h in
0.02%  ethylenediaminetetraacetic  acid  (EDTA)  solution,
stirred vigorously with a flame-polished pipette to disrupt cell
junctions, centrifuged for 5 min at 3000× g, and seeded onto
culture plates coated with FNC coating mix (Athena Enzyme
Systems, Baltimore, MD) containing bovine fibronectin (10
μg/ml) and bovine type I collagen (35 μg/ml). The cells were
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2789cultured  in  OptiMem-I  media  (GIBCO/BRL  Life
Technologies, Grand Island, NY) supplemented with 8% fetal
bovine serum (Cambrex Bio Science, Walkersville, MD), 200
mg/l calcium chloride (Sigma Chemical Co. St. Louis, MO),
0.08% chondroitin sulfate (Sigma Chemical Co.), 20 μg/ml
ascorbic  acid  (Sigma  Chemical  Co.),  100  μg/ml  pituitary
extract (Invitrogen, Grand Island, NY), 5 ng/ml epidermal
growth factor (Sigma Chemical Co.), 20 ng/ml nerve growth
factor  (Sigma  Chemical  Co.),  10  μg/ml  gentamicin
(Invitrogen,  Grand  Island,  NY),  100  IU/ml  penicillin
(Cambrex Bio Science), 100 IU/ml streptomycin (Cambrex
Bio  Science),  and  2.5  μg/ml  amphotericin  (Cambrex  Bio
Science) under 5% CO2. The medium was changed every 2
days. At confluence, the cells were split 1 to 3, and passage 4
cells were used for experiments.
Immunofluorescence  staining:  Human  corneal  endothelial
cells (HCECs) cultured on the coverglasses in 12-well plates
were washed with phosphate buffered saline (PBS) and fixed
for 20 min with 4% paraformaldehyde solution. Cells were
permeabilized with 0.1% Triton X-100 for 10 min and blocked
with 1% bovine serum albumin for 1 h at room temperature.
After  washing,  cells  were  incubated  with  goat  polyclonal
antibody  to  the  α2  chain  of  collagen  VIII  (Santa  Cruz
Biotechnology, Inc., Santa Cruz, CA) overnight at 4 °C and
then  washed  with  PBS.  Cells  were  incubated  with  FITC-
conjugated donkey anti-rabbit IgG antibody (1:100) for 1 h at
37  °C  in  the  dark  and  were  counterstained  with  Hoechst
nuclear staining dye (1:2,000; Molecular Probes, Eugene, OR)
according  to  the  manufacturer’s  recommendations.  After
extensive washing with PBS, the slide was mounted in a drop
of  mounting  medium  to  reduce  photobleaching.  Negative
control staining was performed in parallel with the omission
of primary antibodies.
Purification of clusterin: Clusterin was purified from fresh
normal  human  plasma  as  previously  described  [10,11].
Human plasma was precipitated using 12–23% polyethylene
glycol  (molecular  weight  3,350;  Sigma  Chemical  Co.)
overnight at 4 °C. This precipitate was dissolved and subjected
to  diethylamino  ethanol-sepharose  and  heparin-sepharose
column  chromatography  (GE  Healthcare  Life  Sciences,
Piscataway,  NJ).  Clusterin-positive  fractions  were  then
applied  to  a  clusterin  monoclonal  antibody  affinity
chromatography  column.  The  anti-clusterin  monoclonal
antibody (1G8) was generated using recombinant human full-
length clusterin expressed in Escherichia coli as an antigen,
and  covalently  conjugated  to  cyanogen  bromide-activated
sepharose 4B (Sigma Chemical Co.). The eluted protein was
dialysed against PBS and stored at 280 °C.
Cytotoxicity test: Cytotoxicity was measured using the Cell
Counting  Kit-8  (CCK-8)  assay  (Dojindo  Laboratories,
Kumamoto,  Japan),  which  is  based  on  the  conversion  of
water-soluble  tetrazolium  salt,  WST-8  [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt] to a water-soluble formazan
dye upon reduction in the presence of an electron carrier by
dehydrogenases [22]. Cells (5×104 cells/ml) were treated with
various concentrations (0–50 mM) of tBHP with or without
clusterin for 2 h. The cultures in 96-well plates were placed
in 100 μl of medium that contained CCK-8 and incubated for
3 h at 37 °C. The absorbance at 450 nm was determined by a
multi-plate  reader  (Lamboda  Bio-20;  Beckman,  Inc.,
Fullerton, CA). Cell viability was expressed as a percentage
of the control (untreated) cells.
Measurement  of  intracellular  reactive  oxygen  species
formation:  Production  of  ROS  was  measured  using  an
oxidationsensitive fluorescent probe, 2′7′-dichlorofluorescin
diacetate (DCFH-DA, D6665; Sigma-Aldrich, St. Louis, MO)
methods, based on the ROS-dependent oxidation of DCFH-
DA to DCF. HCECs plated on cover glasses in 12-well plates
(1×106/well) were grown in Chen’s media for 72 h. The cells
were treated with 0, 0.5, 5, 10, 25, and 50 mM tBHP with or
without clusterin (2 μg/ml) at 37 °C for 120 min. Medium was
removed and cells were washed by PBS. Then, 200 μl DCFH-
DA (10μM) was added for 30 min at 37 °C in the dark. The
cells were washed with PBS. Intracellular ROS production
was measured using DCFH-DA by the method previously
described for the DCF-DA microplate assay [23]. We used a
spectrofluorometer  (SFM  25;  Kontron  Instruments)  to
measure  ROS  generation  by  the  fluorescence  intensity  of
10,000 cells in each well at an excitation wavelength of 495
nm and an emission wavelength of 530 nm. Fourteen wells
were used for each concentration of tBHP. The fluorescent
images were taken by an Olympus microscope with a WU (a
near-ultraviolet fluorescence cube) excitation filter (Olympus
Corp., Tokyo, Japan).
Propidium iodide staining: Cell death was assessed by the
uptake of the fluorescent exclusion dye PI. PI is impermeable
to cells with intact plasma membranes, but when a cell’s
integrity becomes compromised, it enters the cells and stains
the nucleus. HCECs (1×105 cells/ml) were plated in 12-well
plates and were treated with 0–50 mM of tBHP with or without
clusterin for 2 h at 37 °C. Cells were washed with PBS and
then stained with 10 μg/ml PI (Sigma Chemical Co.) for 30
min at 37 °C. After washing the cells with PBS, the images
were  obtained  using  an  Olympus  microscope  with  a  WU
excitation filter (Tokyo, Japan).
Measurement  of  caspase-3  activity:  The  activation  of
caspase-3  was  determined  using  the  Caspase-3/CPP32
Colorimetric  Assay  Kit  (BioVision  Inc.,  Mountain  View,
CA). The assay is based on the spectrophotometric detection
of the chromophore pnitroanilide (pNA) after cleavage from
the  labeled  substrate  DEVD  (Asp-Glu-Val-Asp)-pNA.
Comparison of the absorbance of pNA from an apoptotic
sample with an uninduced control allows determination of the
fold increase in CPP32 activity. HCECs (5×104 cells) were
harvested and caspase-3 activity was determined according to
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chromophore p-nitroanilide produced was measured using a
microplate reader (Lamboda Bio-20) at 405 nm. Activity of
caspase-3 was expressed relative to the amount of total protein
in the cell extracts determined using a BCA protein assay kit.
The results were expressed as relative caspase activity.
Statistical analysis: Data were expressed as the mean±SD
from three independent experiments and evaluated using the
Kruskal test, followed by the Mann-Whitney test. Significant
differences were established at p<0.05.
RESULTS
Human  corneal  endothelial  cell  culture:  HCECs  were
cultured as previously described (Figure 1A) [24]. Corneal
endothelial phenotype was verified by the intense positive
staining  with  type  VIII  collagen  alpha  2  monoclonal
antibodies (Figure 1B). The green signal within cytoplasm
indicated collagen VIII alpha 2 synthesis.
Cytotoxicity  test:  HCECs  were  treated  with  various
concentrations of tBHP (0–50 mM) with or without clusterin
(2 μg/ml) for 2 h. The effect of tBHP with or without clusterin
on cell viability was evaluated by CCK-8 assay. tBHP showed
a dose-dependent cytotoxic effect on HCECs (Figure 2). At a
Figure 1. Cultured human corneal endothelial cells. A: A mosaic
pattern is shown. B: Human corneal endothelial cells are positively
stained with anti-collagen VIII alpha 2 antibody (red); DAPI nuclear
staining is blue.
concentration  of  5  mM  tBHP,  tBHP  caused  48.  9±6.8%
decrease in cell viability, and clusterin increased cell viability,
compared with the control (p=0.002 [donor A] and 0.032
[donor B], according to the Mann-Whitney test).
Measurement  of  intracellular  reactive  oxygen  species
formation: To estimate the effect clusterin on the changes in
intracellular  ROS  level  in  cultured  HCECs,  HCECs  were
treated with tBHP (0–50 mM) with or without clusterin for 2
h at 37 °C, and the levels of endogenous ROS were measured
by DCF fluorescence. As shown in Figure 3, compared with
the control group, clusterin-treated groups led to a significant
decrease  in  DCF  fluorescence.  The  results  showed  that
clusterin  could  decrease  the  level  of  intracellular  ROS
significantly in HCECs (Figure 4; p=0.002, 0.002, 0.004, and
0.002 [donor A], and p=0.841, 0.017, 0.017, and 0.029 [donor
B], according to the Mann-Whitney test).
Propidium iodide staining: To determine whether clusterin
inhibits cell death in HCECs, we stained the nuclei with PI.
The  number  of  PI-stained  cells  increased  with  higher
concentrations of tBHP, and decreased in clusterin-treated
groups, compared with the control (Figure 5).
Effects of clusterin in changing caspase-3 activity in human
corneal endothelial cells: Since it is well known that the
caspase cascade is activated during apoptosis, we examined
the effects of clusterin on caspase-3 activity. As shown in
Figure 6, HCECs treated with tBHP with or without clusterin
for 2 h, showed a significant decrease in caspase-3 activity,
Figure 2. Cytotoxicity test using cell counting kit-8 assay. Various
concentrations of tert-Butyl hydroperoxide (tBHP; 0-50 mM) with
or without clusterin (2 μg/ml) were used for 2 h in cultured human
corneal endothelial cells. tBHP showed a dose-dependent cytotoxic
effect on HCECs. At a concentration of 5 mM tBHP, tBHP caused
48.9±6.8% decrease in cell viability and clusterin increased cell
viability, compared with the control (p=0.002, Mann-Whitney test).
A indicates HCECs from a 40-year-old donor. B indicates HCECs
from a 33-year-old donor.
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concentration of 5 mM tBHP, tBHP caused an increase in
caspase-3 activity, and clusterin decreased caspase-3 activity,
Figure  3.  Two-dimensional  dichlorofluorescein  fluorescent
photomicrographs of as human corneal endothelial cells. The cells
revealed higher intensity of fluorescence at higher concentrations of
tert-Butyl  hydroperoxide  (tBHP).  The  clusterin-treated  group
showed lower dichlorofluorescein (DCF) fluorescence, compared to
the control.
compared with the control (p=0.001 [donor A] and 0.0009
[donor B], according to the Mann-Whitney test). These results
indicated that clusterin attenuated the apoptosis of HCECs via
suppression of the caspase cascade.
DISCUSSION
Clusterin is expressed in a broad range of eye tissues [25,26],
including the cornea and conjunctiva in human. It has been
demonstrated that uniform, punctate clusterin staining was
present in a normal corneal endothelium [18]. Clusterin has
been described as being overexpressed in corneal diseases,
including severe ocular surface diseases [27-29] and Fuchs’
endothelial dystrophy [30-32]. However, there has been no
study that investigates the effect of clusterin on HCECs. In the
present study, we treated HCECs with various concentrations
of tBHP, with or without clusterin. tBHP was used as an ROS-
generating agent that could induce oxidative stress. tBHP is
known  to  be  able  to  induce  stress-induced  premature
senescence [3]. In addition, tBHP damages DNA, resulting in
cell death [33,34]. Fuchs’ endothelial dystrophy and bullous
keratopathy have been reported to be related to oxidative
stress [1,2,35] and apoptosis [36,37].
In  the  present  study,  clusterin  decreased  intracellular
ROS induced by tBHP in cultured HCECs. DCF-DA staining
revealed that cells treated with higher concentrations of tBHP
had higher fluorescence, and that cells treated with clusterin
had lower fluorescent intensity, compared to control cells.
Clusterin  significantly  inhibited  tBHP-induced  ROS
production.  These  results  are  compatible  with  previously
described data [3]. Cell viability decreased with higher tBHP
concentration,  and  cells  treated  with  clusterin  had  higher
viability, compared to the control at 5mM tBHP. Clusterin
Figure 4. Relative dichlorofluorescein fluorescence. The formation
of reactive oxygen species (ROS) was assayed by measuring the
fluorescence of dichlorofluorescein (DCF). Each value represents
the mean±SD. The asterisk indicates p<0.05, in comparison with the
control group. A indicates HCECs from a 40-year-old donor. B
indicates HCECs froma 33-year-old donor.
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PI staining showed that clusterin decreased tBHP-induced cell
death (Figure 5). Clusterin appears to be a part of the cellular
response to oxidative stress [38]. It has been suggested that
secretory  clusterin  may  act  as  an  extracellular  molecular
Figure 5. Detection of cell death using propidium iodide staining.
The number of propidium iodide (PI)-stained cells increased with
higher concentrations of tBHP and decreased in clusterin-treated
groups, compared with the control.
chaperone, scavenging extracellular misfolded or denatured
proteins that can be produced following stress-induced injury
[39]. Additionally, it has been proposed that clusterin has
antioxidant properties and is capable of protecting cells from
apoptosis  induced  by  ROS  [40].  The  redox  difference  is
shown  in  the  0  mM  concentration  of  tBHP  in  Figure  3.
Clusterin decreased redox state, even in normal control cells.
This  should  be  investigated  in  further,  molecular-based
studies.
The  viability  results  obtained  by  propidium  iodide
staining  did  not  correlate  well  with  those  obtained  by
cytotoxicity testing. In general, both the PI cytotoxicity assay
and CCK-8 assay have been widely used for determining cell
viability.  However,  the  mechanisms  are  different.  CCK-8
assay is based on the ability of viable mitochondria to convert
water-soluble  tetrazolium  salt,  WST-8,  to  a  water-soluble
formazan dye, upon reduction in the presence of an electron
carrier by dehydrogenases [22]. As for PI, it does not penetrate
the intact plasma membranes that are either viable or in the
early stages of apoptosis. It enters the cells and stainstheir
nuclei in the later stages of apoptosis, or when the cells are
already dead.
Caspases are the cysteine proteases that are crucial for the
process of apoptosis. Caspase 3 functions in the execution of
apoptosis cascades. Increased caspase 3 gene expression or
activity is considered to be one of the hallmarks of apoptosis
induction [41,42]. In the present study HCECs treated with
clusterin showed a significant decrease in caspase-3 activity,
compared with the non-treated control group. These results
indicated that clusterin did attenuate the apoptosis of HCECs
via suppression of the caspase cascade.
Figure 6. Effects of clusterin on the caspase-3 activity in cultured
human  corneal  endothelial  cells.  Activation  of  caspase-3  was
determined by spectrophotometric detection of the chromophore p-
nitroanilide (pNA). Each value represents the mean±SD. The asterisk
indicates a p<0.05, in comparison with the control group. A indicates
human corneal endothelial cells (HCECs) from a 40-year-old donor.
B indicates HCECs from a 33-year-old donor.
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clusterin on HCECs under oxidative stress. The clusterin-
treated group showed high cell viability, low ROS generation,
and low cell apoptosis in HCECs, compared with the control.
Although transgenic Sa OS and U2 OS cell lines adapted to
high intracellular clusterin levels are sensitive to genotoxic
and oxidative stress [43], clusterin has been reported to have
a protective effect against oxidative stress in various cell lines
[7,8,10,44,45],  as  well  as  against  ischemic  tight  junction
protein loss and human retinal endothelial cell death [11]. In
the present study, we used exogenous clusterin purified from
serum. Clusterin in serum is the glycosylated secretary form
(sCLU) [46,47]. It has been demonstrated that the increased
level of the secreted form and the disappearance of the nuclear
unglycosylated  one  (nCLU)  are  directly  connected  to
increased cell survival [12]. Previous studies have indicated a
dose-dependent  effect  of  clusterin  on  the  survival  of  the
cultured cells [48,49].
In  conclusion,  our  data  suggest  that  clusterin  could
protect HCECsfrom oxidative injury-mediated cell death via
inhibition of ROS production. Exogenous clusterin may be
useful as a protective agent during intraocular surgery in old
patients  and  patients  with  Fuchs  endothelial  dystrophy  or
bullous  keratpathy.  In  addition,  it  may  be  useful  as  a
pretreatment agent against corneal endothelial injury occurred
during DMEK, DSAEK, and cultured cell transplantation.
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